Response to lebrikizumab in atopic dermatitis patients who failed upadacitinib: 48-week real-world outcomes. Hagino T, Saeki H, Fujimoto E, Kanda N, et al. J Am Acad Dermatol 2026 Mar 24:S0190-9622(26)00465.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hagino T, Saeki H, Fujimoto E, Kanda N, et al. Response to lebrikizumab in atopic dermatitis patients who failed upadacitinib: 48-week real-world outcomes. J Am Acad Dermatol 2026 Mar 24:S0190-9622(26)00465.
PMID: 41887576